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Objective: The study was conducted to determine whether the different inflation rates of intermittent pneumatic
compression systems used in deep vein thrombosis prophylaxis influence their hematologic and hemodynamic effects.
Methods: A rapidly inflating intermittent calf compression system and a more gently inflating equivalent were applied to
20 healthy male volunteers for 2 hours each. Venous blood samples were taken for analysis of blood coagulation and
fibrinolytic potential. Blood flow velocity was measured in the femoral vein with Doppler ultrasound.
Results: Tissue factor pathway inhibitor significantly increased after the 2 hours of compression for both pumps (78.0 to
85.0 ng/mL rapid, P  .004; 76.5 to 78.0 ng/mL gentle, P  .5), as did plasminogen activator activity (0.85 to 1.05
IU/mL rapid, P  .006; 0.85 to 1.5 IU/mL gentle, P  0.5). Plasminogen activator inhibitor 1 activity was reduced,
although only approaching significance for the gentle system (16.5 to 14.3 AU/mL, P  .06). A D-dimer test for global
fibrinolysis showed significant increases for the gently inflating system (97 to 411 ng/mL P < .001) but not for the
rapidly inflating system (276 to 350 ng/mL P  .9). The rapidly inflating system produced significantly higher venous
peak velocities and augmentations as expected.
Conclusions: Although the data confirm that both types of intermittent compression suppress procoagulant activation,
rapid inflation clearly produced no extra benefit in increasing global fibrinolysis, andmay be less hematologically effective.
(J Vasc Surg 2006;44:1039-45.)The risk of deep vein thrombosis (DVT) and subse-
quent pulmonary embolism has been recognized since at
least 1846, when it was described by Rudolph Virchow,1
who also elucidated the three causal factors: stasis, hyper-
coagulability, and vessel damage. Surgical procedures are
known to produce a high incidence of DVT because muscle
relaxants, anesthetic agents, and surgery itself affect each of
the triad of causes. Pharmacologic prophylaxis is currently
widespread,2 addressing the blood coagulability changes
during surgery; however, excessive bleeding can be a com-
plication. Physical methods of prophylaxis, in contrast, are
less well known and have generally been thought to prevent
venous blood stasis.
Intermittent pneumatic compression has been used to
prevent DVT for 30 years. An automatic pump inflates a
cuff (or cuffs) placed on the lower limbs and, after an interval,
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doi:10.1016/j.jvs.2006.06.016allows deflation in a cycle that can be repeated for as long
as prophylaxis is required. The particular configuration of
the cuffs and pump, the inflation rate and pressure, and the
compression sequence vary between manufacturers. Some
offer graded sequential compression, where several cuffs
inflate sequentially from distal to proximal with progres-
sively reducing pressures, and others promote rapid infla-
tion to achieve, on inflation, high peak blood flow velocities
in the veins proximal to the cuff. Indeed, each system will
have slightly different blood flow velocity effects.
During compression of a cuff, venous blood will be
displaced proximally, and the velocity and duration of that
augmentation of flow in proximal flowwill depend, to some
extent, on the system design. Many previous studies have
investigated the different augmentation properties pro-
duced by compression systems, and yet there has been no
evidence that a particular property, especially high peak
velocities, is linked to lower DVT incidence.3
Venous occlusion had been shown to affect fibrinolysis
before the development of intermittent compression for
DVT prophylaxis,4 and an early study did appear to show
that the effects of the therapy were more than simply
preventing stasis.5 I n a n i n fl uential paper from 1976,
Knight and Dawson6 applied compression cuffs to the arms
of patients and determined that there appeared to be a
prophylactic effect in the legs (ie, the prophylactic effect
could not be purely local). Although that particular work
has not been repeated, there has since been some research
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sion.7-21 The results have been mixed, probably due to the
evolution of techniques of assessing fibrinolysis over time.
We have recently published new evidence obtained from a
D-dimer test for global fibrinolytic potential that showed
that intermittent compression over 2 hours had a signifi-
cant effect.22
The objective of this study was to determine whether two
intermittent compression systems, with known differences in
the expected augmentation velocities on compression, had
different effects on fibrinolysis in healthy volunteers. The link
between flow changes, hematologic changes, and deep vein
thrombosis incidence is unclear, and it was hoped that this
work would provide some further insight.
METHODS
Twenty healthy male volunteers were recruited to take
part in two sessions of intermittent compression each. The
patients were an average SD age of 30 8 years and had
an average SD body mass index of 23.6 3.1. Informed
written consent was obtained, and the research was ap-
proved by the Bro Taf Local Research Ethics Committee.
The subjects were staff of the participating departments.
Potential volunteers were excluded if they were smokers,
had diabetes mellitus, had undergone vascular surgery, or
reported a history of significant cardiovascular disease or
any hematologic disorders. Only men were accepted to
reduce possible cyclical hormonal influences on blood flow.
Although the subject group would not necessarily repre-
sent the at-risk patient population, it minimized confound-
ing factors that might affect either the hematology or the
hemodynamics.
Two intermittent pneumatic compression systems were
applied to both legs with standard pressure settings (de-
scribed below) and activated for a 2-hour session between
9:00 AM and 1:00 PM. The pump that was applied first was
alternated for successive subjects. There were at least 2 days
between the use of each pump.
The first system has a wrap-around garment that has
two air cells in the posterior part. One bladder extends
along the length of the cuff, and the other overlaps the
distal half only. The distal cell inflates rapidly (the pump
pre-pressurizes an internal reservoir before air is released) to
approximately 73 mm Hg before reducing down and sta-
bilizing at 52 mmHg. The proximal cell inflates to 60 mm
Hg 0.3 seconds after the other, reducing to 40 mm Hg
(data from pump literature, and cover of pump). Rapid
inflation would be expected to produce high flow velocities
in veins. The second system, in contrast, has a single pos-
terior bladder in a wrap-around calf garment which inflates
to 40 mm Hg, achieving full pressure gently, in approxi-
mately 2 seconds (measurements by authors). These will be
referred to as the rapid and gentle systems.
A further series of tests was conducted on 20 subjects
(average age 30 7 years), 11 of whomwere part of themain
study group, to give a comparison with more complete and
long-term compression of the leg. A gently inflating thigh and
calf garment was used to compress the calves and thighs to 60mm Hg in a cycle of 1 minute compressed and 1 minute
released for 2 hours, with the experimental protocol otherwise
unchanged from the main study.
Blood samples were obtained from an antecubital vein,
without the use of a tourniquet, immediately before and at
the termination of compression. Venous blood for specific
assays of fibrinolytic components was taken into evacuated
tubes containing 0.1 vol 0.5 M citrate buffer, pH 4.3
(Stabilyte tubes; Biopool International, Ventura, Calif ).
Blood for other assays was taken into evacuated tubes
containing 0.1 vol 0.109 M sodium citrate (Vacutainers,
Becton Dickinson, Franklin Lakes, NJ). Plasma was ob-
tained after centrifugation at 1500g for 10 minutes at room
temperature within 30 minutes of venipuncture and stored
at –80°C in 1.0-mL aliquots. Coagulation tests were per-
formed using conventional clotting methods. von Wille-
brand factor antigen (vWFAg) was measured by enzyme im-
munoassay using commercially available antisera (DAKOLtd,
Bucks, UK), as described by Giddings.23 Tissue factor path -
way inhibitor (TFPI) was measured using an enzyme-
linked immunoabsorbent assay (ELISA, American Diag-
nostica, Stamford, Conn). Tissue plasminogen activator
activity (tPA) and plasminogen activator inhibitor 1 activity
(PAI-1) were measured by chromogenic assays (Chro-
mogenix, Milano, Italy). Factor VIIa was measured in a
clotting assay using recombinant, truncated tissue factor
(TF1-220).
24,25 D-Dimer was quantified using the Mini-
Quant assay (BioStat, Stockport, Cheshire, UK).
Global fibrinolytic potential was measured by adapting
the method described by Haaland et al.26 Briefly, non-
anticoagulated whole blood was allowed to clot at 37°C in
glass test tubes (75  12 mm), and serum was harvested
after 10 minutes and 180 minutes. Levels of D-dimer were
estimated simultaneously on both serum samples. The dif-
ference between D-dimer at these time points specifically
reflected endogenous fibrinolytic activity.
Doppler ultrasound flow velocity measurements were
made immediately after the commencement of intermittent
compression, after 1 hour of intermittent compression, and
immediately before the cessation of intermittent compres-
sion at 2 hours. The SciMed QVL-120 Doppler frequency
spectrum analysis system (SciMed Ltd, Bristol, UK) was
used to obtain three sets of data for each measurement with
a 4MHz continuous wave probe held in a block at 45°. The
strongest venous signal in the region of the common
femoral vein was recorded, with gain settings constant
throughout. Graphic representations of the flow velocity
spectrum covering the resting period before a compression,
any augmentation during compression, and resting flow
after compression were used to extract information about
the maximum velocities and the duration of augmentation.
During measurement, the onset of compression was
noted in the data, and the first 5 seconds of the 6 seconds
before that point were used to determine the maximum
resting velocity, taken from the maximum velocity enve-
lope produced by the system (illustrated in Fig 1). The peak
velocity during augmentation was taken from the point of
compression to the assumed cessation of compression
ters e
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system). The postcompression peak velocity was taken from
the last 5 seconds of the 6 seconds after the cessation of
compression. A measure of the duration of the augmenta-
tion was achieved by calculating the time taken for the
maximum velocity during compression to reduce by half
the difference between it and the maximum velocity before
compression (“half-life of the peak of augmentation”).
Nonparametric statistics were used to analyze these
data (Wilcoxon signed-ranks for paired data, and Mann-
Whitney U test for unpaired data) because of their non-
normal distribution.
RESULTS
A summary of the main results is given in Table I. It can
be seen that there are reductions in PAI-1 activity and vWF
levels (although only approaching the 5% significance level
for the gentle pump), and increases in tPA and TFPI
activity. None of those results, however, demonstrated a
significant difference between the pumps. TheD-dimer test
for global fibrinolysis did demonstrate a highly significant
difference between the systems: Intermittent compression
from the gentle device significantly increased fibrinolysis,
but the rapid device did not produce a significant change.
Although the “before” median values for the two pumps
may appear quite different, this was due to the distribution
of the data, and the difference between the two sets of
values was not statistically significant (Wilcoxon, P  .5).
An apparent difference in the calculated velocity param-
eters (see “Methods”) of the blood flow effects of the
pumps (Table I) was only statistically significant for the
half-lives of the peaks of augmentation. The difference
between the parameters at the beginning and the end for
either pump was not significant.
The only measures where there was a statistically signif-
icant difference between the methods were  D-dimer and
Maximum 
velocity pre-
compression 
Maximum 
velocity during 
compression 
Augmentation Velocity 
Precompression 
5 seconds 
Compre
Fig 1. Illustration of the hemodynamic paramepeak half-life, but there was no statistically significant cor-relation between  D-dimer and the velocity parameters
(Spearman’s rho coefficient, significance to 5% level).
A summary of the results of the further test with calf
and thigh compression at 60 mm Hg and a slow cycle is
given in Table II. The significance of the reduction in factor
VIIa was close to the 5% level, unlike the results for the
other two pumps, but more noticeable was the lack of a
change in the TFPI levels. Global fibrinolytic potential
increased as with the other systems. The statistical compar-
isons of the changes showed, however, that the D-dimer
change was significantly different from that achieved with
the normal gentle system (ie, a smaller change) but not
different from the change for the rapid system. The three
sets of data were not compared together directly, but in
pairs, because the volunteer group was different for the
third set and the primary question was the comparison
between the slow and gentle cycles. Graphs illustrating the
comparisons for factor VIIa, TFPI, andD-dimer change are
given in Fig 2.
DISCUSSION
Although the efficacy of intermittent compression in
preventing DVT has been demonstrated many times in
recent decades,27 there has been little firm proof of how the
properties of the acute hemodynamic and hematologic
changes affect prophylaxis. Blood flow velocity changes
have been quite simple to demonstrate; therefore, the focus
of development of intermittent compression systems has
been in improving velocity-related parameters such as the
peak velocity during compression and the percentage aug-
mentation, both of which were measured in this study.
Systems have been developed where the inflation rate is
very short and the impact on the limb is maximized to
produce very high peak velocities. It has been supposed that
a high velocity may strip any forming thrombi from veins
Half-life of the 
peak of 
augmentation 
Maximum 
velocity post-
compression 
Postcompression 
5 seconds 
 period 
Time
xtracted from each flow velocity measurement.ssionbefore they can develop clinical significance and would pro-
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mon and the initial growth of thrombi is concentrated.28,29
Rapid inflation of a cuff will also make the action more
Table I. A comparison of the hematologic and hemodyna
Rapid system
Before After
vWF (IU/mL) 85.0 [92.4] 82.5 [91.6]
(74.0-117.5) (73.3-112.5)
P  .27 (CI, 3, 1)
tPA (IU/mL) 0.85 [0.88] 1.05 [1.13]
(0.53-1.10) (0.90-1.58)
P  .006 (CI, 0.1, 0.4)
PAI-1 (AU/mL) 15.5 [15.6] 15.3 [15.1]
(12.1-18.0) (11.0-18.0)
P  .61 (CI, 1.8, 1.0)
Factor VIIa (mU/mL) 90 [98] 95 [104]
(77-113) (82-122)
P  .41 (CI, 6, 15)
TFPI [total] (ng/mL) 78.0 [76.3] 85.0 [80.2]
(59.3-87.5) (63.3-96.0)
P  .004 (CI, 2, 7)
 D-dimer (ng/mL) 276 [598] 350 [512]
(57-1161) (139-597)
P  .87 (CI, 299, 229)
Beginning End
Peak velocity (cm/s) 34.9 [37.7] 32.0 [35.8]
(26.3-43.8) (21.4-47.9)
P  .98 (CI, 8.8, 7.7)
Augmentation (%) 304 [390] 290 [287]
(197-537) (190-393)
P  .20 (CI, 179, 42)
Peak half-life (s) 0.27 [0.29] 0.28 [0.27]
(0.17-0.41 (0.19-0.34)
P  .45 (CI, 0.08, 0.05)
vWF, von Willebrand factor; CI, confidence interval; tPA, tissue plasminoge
pathway inhibitor.
*The data are medians of the values for the 20 patients, with the exception o
values of three readings taken at the appropriate times. Interquartile range
difference between the before and after (or beginning and end) values are
two-tailed), with the 95% CIs. The statistical significance of the differences
†For the hematology assays, this is a comparison of the changes (before-aft
hemodynamic indices this is a comparison of the average value (beginning,
Table II. Comparisons between the slow cycle data and th
Slow compr
Before
Factor VIIa (mU/mL) 85 [81] (58-96)
P  .06 (CI, 
TFPI [total] (ng/mL) 65.0 [65.7] (51.0-76.8)
P  .8 (CI, 
 D-dimer (ng/mL) 115 [287] (14-227)
P  .006 (CI,
TFPI, Tissue factor pathway inhibitor.
*Comparisons between the pump data were assessed with the Mann-Whitne
slow cycle were Wilcoxon, as in Table I.noticeable to patients, however, and may affect their com-pliance. A considerable problem of mechanical methods of
DVT prophylaxis is misapplication of stockings and cuffs
and insufficient use of intermittent compression.30,31 If
results for the rapid and gentle compression systems*
Gentle system
Pump difference†Before After
5.0 [89.7] 84.5 [87.3] P  .27 (CI, 1.5, 4.5)
9.5-105.3) (66.3-103.8)
P  .05 (CI, 5, 0)
.85 [0.99] 1.15 [1.20] P  .65 (CI, 0.15, 0.25)
.63-1.29) (0.83-1.71)
P  .05 (CI, 0.0, 0.4)
6.5 [19.9] 14.3 [18.4] P  .18 (CI, 0.5, 2.5)
2.6-18.0) (9.5-17.8)
P  .06 (CI, 3.0, 0.0)
98 [111] 95 [106] P  .23 (CI, 5, 23)
(78-131) (78-118)
P  .16 (CI, 12, 5)
6.5 [75.0] 78.0 [78.0] P  .33 (CI, 2.5, 6.5)
9.0-88.8) (62.0-94.8)
P  .05 (CI, 0, 6)
97 [484] 411 [924] P  .008 (CI, 724, 84)
(25-448) (76-1299)
P  .001 (CI, 128, 562)
eginning End
6.4 [18.3] 19.0 [19.1] P  .71 (CI, 10.1, 7.4)
4.1-20.3) (12.5-23.6)
P  .74 (CI, 2.4, 3.6)
60 [102] 56 [83] P  .40 (CI, 162, 59)
(35-109) (37-85)
P  .44 (CI, 51.7, 12.1)
.19 [0.26] 0.23 [0.28] P  .04 (CI, 0.07, 0.41)
.09-0.42) (0.13-0.38)
P  .91 (CI, 0.06, 0.10)
vator; PAI-1, plasminogen activator inhibitor 1 activity; TFPI, tissue factor
ow velocity results, where they are medians for the 20 patients of the mean
iven in parentheses below each value, and the statistical significance of the
below those (Wilcoxon signed-ranks nonparametric test for paired data,
en the pumps is given in the final column (Wilcoxon).
m one pump, with the changes from the other (also before-after), for the
e, end), for each pump.
from the rapid and gentle pumps*
Rapid
comparison
Gentle
comparisonAfter
75 [73] (47-91) P  .06 P  .6
0)
.0 [64.7] (52.0-76.0) P  .001 P  .04
62 [398] (87-523) P  .3 P  .02
19)
st for independent samples, and the tests of the changes before and after themic
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intermittently compressing a particular limb would expose
that limb to increased risk of thrombosis.
The data in this and the previous report22 are valuable
because earlier investigations of fibrinolytic activity have
produced conflicting results. Global tests in the earliest
work, such as the euglobulin lysis time, indicated increased
fibrinolysis during intermittent compression, whereas more
recent studies of specific assays of fibrinolytic proteins have
given inconsistent results.12-14,17,19-21 Indwelling cathe-
ters were avoided in this investigation to prevent the con-
sequent elevations in tPA and PAI that have been observed
to last for several hours.32 Moreover, we and others have
shown that measurements of these fibrinolytic components
using ELISA may not reflect enzyme activity.22 It has also
been confirmed that intermittent compression has a favor-
able effect in moderating procoagulant activation by mod-
erating the tissue factor pathway.16
The results emphasize that endogenous fibrinolysis is
governed by a number of interdependent mechanisms, not
only those involving the commonly measured parameters
of tPA and PAI-1. In this context, it might be especially
significant that reduced activity of the tissue factor pathway
could be expected to depress the local generation of throm-
bin and hencemodulate the activity of thrombin activatable
fibrinolytic inhibitor (TAFI).33,34 Recent reports that
plasma kallikrein activates pro-urokinase (pro uPA) or plas-
minogen, or both, resulting in plasmin generation,35 and of
a novel factor VII-activating serine protease that is a potent
activator of pro-uPA in vivo36 further illustrate the com-
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    Rapid    Slow      Gentleplexity of these mechanisms.CONCLUSION
The principal objectives of the current work were (1) to
determine whether two systems with known differences in
function and typical velocity parameters would both affect
fibrinolysis and (2) to determine any difference between
those effects. The difference in the influence on global
fibrinolysis was entirely unexpected. It is not clear why the
gentle system appeared to increase global fibrinolysis con-
sistently and the rapid system did not. It could be specu-
lated that somehow a rapid pressure rise-time is undesir-
able, not giving enough time for flow changes to affect the
vascular endothelium. It is also possible that the longer
period of compression of the gentle system (12 seconds vs
6 seconds) is beneficial. The duration of augmentation of
the two systems was not statistically different, however, and
the data for the longer duration higher-pressure cuff with
greater limb coverage did not produce better results. The
slow cycle results for global fibrinolysis were more like
those for the rapid system. It is plausible that the compres-
sion duration of the normal gentle cuff passes a threshold
necessary to produce the maximum effect that the rapid
system does not reach. The results of the higher pressure,
longer duration, greater coverage compression further sug-
gest that not only is longer compression not beneficial but
that it may reduce effectiveness in the same way that is
apparent from too-rapid compression.
If it can be shown that rapidly inflating systems gener-
ally do have poorer hematologic effects, then it should lead
to a re-evaluation of the parameters used in the design of
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aintermittent compression systems and the assumptions that
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link between prevention of venous stasis and the changes in
blood coagulability that have been observed are not clear
and deserve further research. In addition, the reasons for
the variability of the hematologic assays in response to
intermittent pneumatic compression in the current investi-
gations remain to be determined.
There is a growing literature on the role of gene poly-
morphisms and the environment in the control of hemo-
static mechanisms,37,38 and in a relatively small study of this
nature, the results might be influenced by the characteris-
tics of individual volunteers. Recent evidence suggests that
there is also an association between TAFI genotype and
TAFI levels in plasma39 and between factor VII-activating
serine protease genotype and fibrinolytic potential.40 These
findings might have further impact on global hemostatic
variables.
Nevertheless, the general confirmation that intermit-
tent compression affects systemic fibrinolysis offers the
hope that compression of limbs other than those consid-
ered at risk of DVT could provide at least some prophylaxis
for all limbs, although there is no current evidence linking
particular levels of fibrinolytic activity produced by inter-
mittent compression to DVT outcomes. However, the
possibility that certain systems may not provide optimal
prophylaxis because of too-rapid compression, as suggested
by a recent clinical study,41 must be considered in patient
management if these results are also confirmed in patient
groups.
We are grateful to Dr John McVey of Imperial College
London for the generous gift of recombinant soluble tissue
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